Skip to main content

Table 4 Changes in the responders and non- responder following 24 weeks treatment

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Variables

Responder group (n = 23)

Non-responder group (n = 6)

Baseline

24 weeks

Baseline

24 weeks

Body weight (kg)

66.8 ± 16.3

67.3 ± 17.4

62.4 ± 14.8*

64.3 ± 15.9

Waist Circumference (cm)

97.6 ± 12.2

98.0 ± 12.1

84.6 ± 85**

85.9 ± 8.4

Total insulin dose (units/day)

71.3 ± 14.9

32.1 ± 14.0

59.8 ± 12.9 **

54.5 ± 14.7##

HbA1c (%)

9.5 ± 1.2

7.8 ± 1.1

8.6 ± 1.3*

8.4 ± 1.1##

FBG (mmol/L)

12.0 ± 2.7

7.4 ± 1.4

9.8 ± 2.1*

9.2 ± 1.5##

P2BG (mmol/L)

16.7 ± 4.8

9.8 ± 2.4

16.3 ± 4.2

15.8 ± 4.2##

HMW adiponectin (ug/ml)

2.89 ± 1.54

5.79 ± 1.58

4.74 ± 1.46**

5.11 ± 1.52##

  1. Normally distributed data expressed as mean ± standard deviation and non-normally distributed data expressed as median or as numbers and percentages. Non-normally distributed data were logtransformed for use with parametric statistics. HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; HMW: high-molecular weight; Data are mean ± SD. *p < 0.05 and **P <0.01 for responder vs. non-responder at baseline; #p<0.05 and ##p<0.01 for absolute changes in responder vs. non-responder following 24 weeks glimepiride treatment.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us